Viknesh Sounderajah, Ahmad Guni, Xiaoxuan Liu, Gary S. Collins, Alan Karthikesalingam, Sheraz R. Markar, Robert M. Golub, Alastair K. Denniston, Shravya Shetty, David Moher, Patrick M. Bossuyt, Ara Darzi, Hutan Ashrafian
{"title":"The STARD-AI reporting guideline for diagnostic accuracy studies using artificial intelligence","authors":"Viknesh Sounderajah, Ahmad Guni, Xiaoxuan Liu, Gary S. Collins, Alan Karthikesalingam, Sheraz R. Markar, Robert M. Golub, Alastair K. Denniston, Shravya Shetty, David Moher, Patrick M. Bossuyt, Ara Darzi, Hutan Ashrafian","doi":"10.1038/s41591-025-03953-8","DOIUrl":null,"url":null,"abstract":"<p>The Standards for Reporting Diagnostic Accuracy (STARD) 2015 statement facilitates transparent and complete reporting of diagnostic test accuracy studies. However, there are unique considerations associated with artificial intelligence (AI)-centered diagnostic test studies. The STARD-AI statement, which was developed through a multistage, multistakeholder process, provides a minimum set of criteria that allows for comprehensive reporting of AI-centered diagnostic test accuracy studies. The process involved a literature review, a scoping survey of international experts, and a patient and public involvement and engagement initiative, culminating in a modified Delphi consensus process involving over 240 international stakeholders and a consensus meeting. The checklist was subsequently finalized by the Steering Committee and includes 18 new or modified items in addition to the STARD 2015 checklist items. Authors are encouraged to provide descriptions of dataset practices, the AI index test and how it was evaluated, as well as considerations of algorithmic bias and fairness. The STARD-AI statement supports comprehensive and transparent reporting in all AI-centered diagnostic accuracy studies, and it can help key stakeholders to evaluate the biases, applicability and generalizability of study findings.</p>","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"78 1","pages":""},"PeriodicalIF":50.0000,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41591-025-03953-8","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
The Standards for Reporting Diagnostic Accuracy (STARD) 2015 statement facilitates transparent and complete reporting of diagnostic test accuracy studies. However, there are unique considerations associated with artificial intelligence (AI)-centered diagnostic test studies. The STARD-AI statement, which was developed through a multistage, multistakeholder process, provides a minimum set of criteria that allows for comprehensive reporting of AI-centered diagnostic test accuracy studies. The process involved a literature review, a scoping survey of international experts, and a patient and public involvement and engagement initiative, culminating in a modified Delphi consensus process involving over 240 international stakeholders and a consensus meeting. The checklist was subsequently finalized by the Steering Committee and includes 18 new or modified items in addition to the STARD 2015 checklist items. Authors are encouraged to provide descriptions of dataset practices, the AI index test and how it was evaluated, as well as considerations of algorithmic bias and fairness. The STARD-AI statement supports comprehensive and transparent reporting in all AI-centered diagnostic accuracy studies, and it can help key stakeholders to evaluate the biases, applicability and generalizability of study findings.
期刊介绍:
Nature Medicine is a monthly journal publishing original peer-reviewed research in all areas of medicine. The publication focuses on originality, timeliness, interdisciplinary interest, and the impact on improving human health. In addition to research articles, Nature Medicine also publishes commissioned content such as News, Reviews, and Perspectives. This content aims to provide context for the latest advances in translational and clinical research, reaching a wide audience of M.D. and Ph.D. readers. All editorial decisions for the journal are made by a team of full-time professional editors.
Nature Medicine consider all types of clinical research, including:
-Case-reports and small case series
-Clinical trials, whether phase 1, 2, 3 or 4
-Observational studies
-Meta-analyses
-Biomarker studies
-Public and global health studies
Nature Medicine is also committed to facilitating communication between translational and clinical researchers. As such, we consider “hybrid” studies with preclinical and translational findings reported alongside data from clinical studies.